The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Reevaluating Goals of Therapy in Primary Biliary Cholangitis: Is Good Enough Is Not Good Enough Anymore?
Am J Gastroenterol. 2020 Jul;115(7):1024-1025. doi: 10.14309/ajg.0000000000000693.
Richard J Bower1, Catherine Frenette2
Author information
1Department of Gastroenterology, Naval Medical Center San Diego, San Diego, California, USA.
2Division of Organ Transplant, Department of Medicine, Scripps Green Hospital, La Jolla, California, USA.
Abstract
Primary biliary cholangitis (PBC) is an autoimmune-mediated inflammatory cholestatic liver disease, which can progress to cirrhosis. This issue of The American Journal of Gastroenterology features the results of the GLOBAL PBC Study Group evaluating patients with PBC over a 10-year period. Although biochemical response was evaluated in previous studies, this study showed that bilirubin levels ≤0.6 upper limit of normal or normal levels of alkaline phosphatase are associated with the lowest risk for liver transplantation or death in patients with PBC.
Stay Informed!
